
Assistant Professor, (GU/Melanoma) @RushCancer| Chief Fellow @OSUCCC_James | Internal Medicine @MSMEDU | Associate Editor @TheMedNet| Immunotherapy outcomes
Chicago
Joined April 2013
- Tweets225
- Following331
- Followers164
- Likes100
Manan Shah retweeted
Today the FDA approved neoadjuvant EV and perioperative duvalumab in muscle invasive bladder during #UromigosLive . This is based on a +ve EFS & OS signal This gives and addition option to 9 cycles of perioperive EVP already approved. @Annals_Oncology @myESMO @OncoAlert google.com/goto?url=CAEStgEB…
Manan Shah retweeted
JUST IN: @FDA approves peri-operative PD-L1 inhibitor Durvalumab + EV in cis-ineligible/refusing Muscle-Invasive Bladder Cancer (MIBC), based on #VOLGA presented #ESMO26 by @tompowles1 and published @NEJM
-2yr EFS 64% vs 45% (HR 0.51)
-2yr OS 78% vs 69% (HR 0.58)
-pCR 45% vs 10%
@OncoAlert @OpenMedInsights @DanaFarber_GU @OncBrothers @AUC3_Official @DrRanaMcKay @DrRosenbergMSK @montypal
Manan Shah retweeted
#UromigosLIVE score for adjuvant ccRCC trials
🌀 Pembro alone undisputed SOC #KN564
☄️ Doublet pembro/belzutifan potentially inferior to SOC but a reasonable option #LITESPARK022
@OncoAlert
Today the American Cancer Society made important changes to their prostate cancer screening guidelines: Men 50 to 69 should get a PSA test every two years; Black men and men with a family history of prostate cancer should get one every year starting at 45; and starting at age 70, men should talk to their doctors about what's right to them.
I know firsthand the toll of this disease, and I know that catching it early saves lives.
So talk to your doctor, get screened, and let’s keep working to end cancer as we know it.
As rates of advanced prostate cancer continue to rise, the American Cancer Society is recommending that most men ages 50 to 69 get screened every other year. nbcnews.com/health/cancer/ne…
Manan Shah retweeted
Next - what will have the greatest impact in mCRPC - RIPTAC or T cell engagers - logistics of admin, response rates & durability, toxicity
Point made this is like comparing apples & oranges, we need both ☄️
@shilpaonc came out winning for RIPTACs #UromigosLIVE @OncoAlert
Manan Shah retweeted
Management of #mCRPC: Personalized Treatment Selection and Sequencing. Presented by Dr. Deborah Mukherji, MBBS, FRCP. #ESMO26 written coverage by @zklaassen_md > bit.ly/4eSjvGU #ProstateCancer #PrecisionOncology @myESMO
Manan Shah retweeted
FDA approved talazoparib plus enzalutamide for HRR-mutated mHSPC/APMN based on TALAPRO-3.
📜 Combination vs enzalutamide: rPFS HR 0.48, 36-month rPFS 77% vs 56%
🧬 BRCA1/2 HR 0.37 and non-BRCA HRR HR 0.57, post hoc, with wide intervals, so no BRCA-specific claim
⚠️ Grade 3 or 4 events 79% vs 41%
🔍 OS is immature, interim HR 0.77 with a CI crossing 1
👉 bit.ly/FDA-Talazoparib-HRRm
#ProstateCancer #ProstateCA #GUonc
Manan Shah retweeted
📣 another FDA approval in APMS
➡️ MANY in 2026 inc. pluvicto & capivasertib
➡️ now talazoparib/enza vs enza #TALAPRO3 for HRR-altered APMS (vs AMPLITUDE only BRCA2)
➡️ rPFS 77% vs 56% (HR 0.48)
⚠️ OS immature, G≥3 anemia 51%, 40% transfused; no docetaxel-triplet comparator
Manan Shah retweeted
Agree - this was a terrific session all around. All speakers offerd practical advice on management of #raretumors in the GU space; pearls that will definitely help in the clinic on Monday. @oncoalert @mdesantis234 @AndreaNecchi @DrTiborSzarvas @b_szabados @crisuarez08
Insightful talk on small cell neuroendocrine carcinoma of bladder by #MariaDeSantis.
Platinium remains the backbone. DLL3 is a promising therapeutic target.
#ESMO26 #Day2 @myESMO @OncoAlert
Manan Shah retweeted
Incredible to see work on the very rare RCC subtypes: collecting duct & renal medullary CA at #ESMO26
#REPRINT trial testing EV + P
🎯 22% ORR & 55% DCR overall ➡️ moving to stage 2!
Also very impt trials from @PavlosMsaouel in RMC on: ubamatamab, Sac-TMT, panitumumab…
Manan Shah retweeted
Kudos @tompowles1 on a fantastic #VOLGA presidential @ #ESMO26 👏
Less is More!
• Cis-inelig MIBC, 25% were cis refusers
• D+EV x3 → RC → adj D x9 (NO adj EV)
• EFS HR 0.51
• OS HR 0.58
• pCR 45 vs 10%
• G3-4 TRAE 30%,
• neuropathy only 18%
• imAEs 33% (G3-4 11%)
• GHS/QoL maintained post-RC
• Treme ↑tox (G3-4 42%, 5 deaths), NO OS gain.
My take: it's not just about chasing bigger numbers. Tox matters too, especially when OS is achieved. Need to discuss the pros and cons with patients.
Less PN and skin tox, and fewer G3+ immune AEs than more cycles and that's a win for patients ! 🙌
@Uromigos @OncoAlert @brian_rini @LosUromigos @drenriquegrande
The #ESMO26 Presidential Symposium is about to begin! 🔥
Super excited to hear the highly anticipated results of the VOLGA trial, presented by the the only and only @tompowles1!
@myESMO
@apolo_andrea @Uromigos @brian_rini @OncoAlert @LosUromigos @uromigosjapan @MichvdHeijden
Manan Shah retweeted
Incredible cancer breakthrough #ESMO26 w/ new benchmark in melanoma & huge advances for all future personalized tx that could extend to other cancers
🌟 Ph3 Intismeran autogene mRNA vaccine improved RFS by 42% w/ Pembro vs Pembro alone, distant mets reduced by 38%, similar AEs
Manan Shah retweeted
KEYNOTE-B15 ctDNA analysis presented by Jonathan Chatzkel at #ESMO26, with Min Teo as discussant 🧬 In cisplatin-eligible MIBC, ctDNA+ before surgery meant almost no pCR with either regimen (3.7% with EV + pembro, 2.2% with cis/gem). Among ctDNA− patients, pCR was 72.4% with EV + pembro vs 43.7% with cis/gem. In the EV + pembro arm, patients who cleared ctDNA had 24-month EFS of 81% vs 33% with persistent ctDNA+. The postsurgery results replicate NIAGARA. Serial ctDNA could open the door to bladder-sparing and surveillance questions. #MRD #ctDNA #BladderCancer
Manan Shah retweeted
Encouraging OS results in neuroendocrine prostate cancer at #ESMO26!
#KEYNOTE-365 evaluated pembrolizumab + carboplatin/etoposide vs chemotherapy alone.
• mOS: 10.2 vs 7.1 months (HR 0.33)
• rPFS: 5.1 vs 4.0 months (HR 0.66)
• PD-L1 CPS ≥1: mOS 11.0 vs 4.8 months (HR 0.16)
No new safety signals observed.
@myESMO @oncoalert
Manan Shah retweeted
Replying to @DrRanaMcKay
@DrRanaMcKay @UCSDHealth and @mishabeltran @DanaFarber_GU co-lead @ALLIANCE_org A032102/PREDICT evaluating if genetic testing helps determine the best treatment regimen for men with metastatic prostate cancer. Learn more: bit.ly/Alliance-A032102 #PCsm #clinicaltrials
Manan Shah retweeted
⚡️ Phase 2 trial in RCC with inferior vena cava tumor thrombus: neoadjuvant stereotactic ablative radiotherapy (SAbR) followed by surgery (n=23).
1-year recurrence-free survival: 71.4% — above the 55.7% historical benchmark. Thrombus downstaging in 22%.
A promising approach for one of the most challenging complications in kidney cancer.
#KidneyCancer #RCC @JAMAOnc
jamanetwork.com/journals/jam…
Manan Shah retweeted
⚡️ KEYNOTE-427 final results (61 months follow-up) in @annalsofoncology: pembrolizumab monotherapy in first-line advanced ccRCC and nccRCC — ORR 36.4% and 26.7%, respectively.
PD-L1 CPS and T-cell-inflamed GEP associated with outcomes in both cohorts. Baseline ctDNA positivity linked to shorter OS (30.5 vs 53.7 months).
annalsofoncology.org/article…
#KidneyCancer #Immunotherapy
Manan Shah retweeted
Once in a while I get to read an article so good that I hope the rest of the world also reads it. Go home, drink the good wine, and read this. Superb editorial from @Prof_IanD : ascopubs.org/doi/10.1200/OP-…
Manan Shah retweeted
🗣️ The updated @myESMO guidelines for advanced and metastatic #ProstateCancer are a pleasure to read.
🙏 Huge clarity to an increasingly complex field: elegant treatment algorithms, practical guidance for clinical decisions, and recommendations that are clear about the strength of the evidence. I particularly appreciate that the authors are willing to take a position where clinicians need one.
Congratulations and thanks to #KarimFizazi and the entire international, multidisciplinary author group. This is a valuable resource for all of us caring for patients with prostate cancer, wherever we practise.
I would love to hear what colleagues around the world find most useful in the new algorithms.
Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆ - Annals of Oncology annalsofoncology.org/article…






















































